February 5, 2025
Novo Nordisk Q4 '24 Earnings Call: Obesity Medicine Implications
On The Pen With Dave KnappAbout this episode
From high dose semaglutide to cagrisema launch dates, Dave Knapp discusses how the latest Novo Nordisk earnings call impacts patients. Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp 📱 Amazon Kindle Reader: https://amzn.to/4gAXrz4 📖Paperback: https://amzn.to/4gAXrz4 💊 Peptide Supplement I Use: https://integrativepeptides.com/AFFILITATES/OTP USE CODE "OTP10" to save 10%. SOCIALS: 📸 : https://www.instagram.com/onthepen.official/profilecard/?igsh=dTRhY3JkYWo1bTIx 🇨🇳: https://www.tiktok.com/@manonthemounjaro?_t=ZP-8sr5PrUuPQl&_r=1 👾: https://discord.gg/ZHeUh7WV 📺: https://youtube.com/@ManOnTheMounjaro?feature=shared ❌: https://x.com/manonthepen?s=21 💻: https://www.onthepen.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.